Cargando…

A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes

IMPORTANCE: Based on efficacy results from pivotal randomized clinical trials, PD-1 (programmed cell death 1) inhibitors, such as nivolumab and pembrolizumab, have been approved to treat various cancers. Response patterns with varying effects on progression-free survival (PFS) and overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gyawali, Bishal, Hey, Spencer Phillips, Kesselheim, Aaron S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324401/ https://www.ncbi.nlm.nih.gov/pubmed/30646078 http://dx.doi.org/10.1001/jamanetworkopen.2018.0416

Ejemplares similares

A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer
por: Gyawali, Bishal, et al.
Publicado: (2021)

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis
por: Gyawali, Bishal, et al.
Publicado: (2019)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis
por: Kok, Peey-Sei, et al.
Publicado: (2020)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis
por: Addeo, Alfredo, et al.
Publicado: (2019)

Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis
por: Zhou, Zhirui, et al.
Publicado: (2021)

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
por: Iivanainen, Sanna, et al.
Publicado: (2019)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
por: Paoletti, Xavier, et al.
Publicado: (2020)

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2020)

Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys
por: Feldman, William B., et al.
Publicado: (2019)

Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2019)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
por: Chowdhury, Simon, et al.
Publicado: (2020)

Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
por: Okabe, Ayano, et al.
Publicado: (2023)

Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases
por: Carpenter, David J., et al.
Publicado: (2023)

An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion
por: Hey, Spencer Phillips, et al.
Publicado: (2016)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
por: Wang, Zi-Xian, et al.
Publicado: (2019)

Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007–2016
por: Hwang, Thomas J, et al.
Publicado: (2018)

Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study
por: Gyawali, Bishal, et al.
Publicado: (2021)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
por: Lee, Jae Ho, et al.
Publicado: (2017)

Overall and Cervical Cancer Survival in Patients With and Without Mental Disorders
por: Herweijer, Eva, et al.
Publicado: (2023)

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial
por: Chibaudel, Benoist, et al.
Publicado: (2020)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
por: Burzykowski, Tomasz, et al.
Publicado: (2019)

Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis
por: Ye, Jiabu, et al.
Publicado: (2020)

Nicotinamide N-methyltransferase is overexpressed in prostate cancer and correlates with prolonged progression-free and overall survival times
por: ZHOU, WEIMIN, et al.
Publicado: (2014)

Prognostic factors for progression‐free and overall survival in malignant pleural mesothelioma
por: Guzmán‐Casta, Jordi, et al.
Publicado: (2021)

Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
por: Solomon, B.J., et al.
Publicado: (2022)

Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review
por: Chase, Dana M, et al.
Publicado: (2023)

Functional connectivity within glioblastoma impacts overall survival
por: Daniel, Andy G S, et al.
Publicado: (2020)

Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer
por: Tobias, Claire J., et al.
Publicado: (2020)

Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival
por: Yang, Daniel X., et al.
Publicado: (2021)

Overall Survival After Treatment Failure Among Patients With Rectal Cancer
por: Diefenhardt, Markus, et al.
Publicado: (2023)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Quantifying the association between progression‐free survival and overall survival in oncology trials using Kendall's τ
por: Weber, Enya M., et al.
Publicado: (2018)

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
por: Belin, Lisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0esfhq3gf6gscpl7v8vr6qc9bn